Preliminary development validation

Wu, A.H.B., Fukushima, N., Puskas, R., Todd, J., and Goix, P. (2006) Development and preliminary clinical validation of a high sensitivity assay for cardiac troponin using a capillary flow (single molecule) fluorescence detector. Clinical Chemistry, 52, 2157 2159. 

W. Schalm, G.P. Van Berge-Henegouwen, A.F. Hofmann, A.E. Cowen and J. Turcotte, Radioimmunoassay of bile acids development, validation, and preliminary application of an assay for conjugates of chenodeoxycholic acid. Gastroenterology 73 285 (1977). 

Two activity coefficient models have been developed for vapor-liquid equilibrium of electrolyte systems. The first model is an extension of the Pitzer equation and is applicable to aqueous electrolyte systems containing any number of molecular and ionic solutes. The validity of the model has been shown by data correlation studies on three aqueous electrolyte systems of industrial interest. The second model is based on the local composition concept and is designed to be applicable to all kinds of electrolyte systems. Preliminary data correlation results on many binary and ternary electrolyte systems suggest the validity of the local composition model. 

Finally, there are custom two-step quantitation methods such as chromatography or ELISA that require a capture step for isolating the protein and then a quantitation step based on a standard curve of the purified target protein. The preliminary capture step may also concentrate the protein for increased sensitivity. These techniques are typically not available in a commercial kit form and may require extensive method development. They are more labor intensive and complex than the colorimetric or absorbance-based assays. In addition, recovery of the protein from and reproducibility of the capture step complicate validation. Despite these disadvantages, the custom two-step quantitation methods are essential in situations requiring protein specificity. 

The preliminary models can be used to select compounds for synthesis and to determine which data is most important to generate to understand the PK properties of a particular compound or series. As compounds are generated and at first low-throughput and then high-throughput data become available, the model can be updated and when possible validated against in vivo PK data in animals. Mismatches between model predictions and data indicate missing mechanisms or inadequate data. If the model prediction does not match the data, the model can be used to develop... 

Dawson DA, Bande JA (1987) Development of a reconstituted water medium and preliminary validation of the frog embryo teratogenesis assay Xenopus (EETAX). J Appl Toxicol 7(4) 237-244... 

These preliminary observations demonstrate the feasibility of applying pharmacogenetics from the start of clinical development and the potential to elucidate relevant hypotheses from a relatively small sample size, although the results require replication and validation. Testing these hypotheses will require confirmation in a larger patient population (i.e., from phase 11/111 studies), which should also enable an assessment of the magnitude of effect and attributable risk. 

The added value of single-laboratory validation is that it simplifies the next step—interlaboratory validation—and thereby minimizes the gap between internally (validated or not) developed methods and the status of interlaboratory validation. By optimizing the method first within the laboratory, as a kind of preliminary work, an enormous amount of collaborators time and money is saved [58]. 

The suitability of a method for its intended use should be proven in initial experiments. These introductory studies should include the approximate precision, accuracy, detection limit, and working range. If these preliminary validation data appear to be inappropriate, either the method itself or the acceptance limits should be changed. The developer does not know whether the method conditions are acceptable until validation studies are performed. Results of validation studies may indicate that a change in the procedure is necessary, which may then require revalidation. In this way, method development and validation seems to be an iterative process during each developmental phase, key method parameters are determined and then used for all subsequent validation steps. 

Analytical testing (preformulation, stability, product release) is a core component of pharmaceutical operations from early R D through manufacturing of the commercial product. The original analytical methods are usually developed by the pioneer pharmaceutical firm and transferred to the provider. In some cases, the early methods are only preliminary methods and are not sufficiently robust to test the quality of downstream (clinical, commercial, and line extension) products and facility quality practices (cleaning validation). In those situations, the supplier is often asked to develop new methods, and in some cases those methods are transferred back to the client. In either scenario, the transfer of validated analytical methodology consists of the following four main tasks [52] ... 

If there is no or little information on the method s performance characteristics, it is recommended that the method s suitability for its intended use in initial experiments be proven. These studies should include the approximate precision, working range, and detection limits. If the preliminary validation data appear to be inappropriate, the method itself, the equipment, the analysis technique, or the acceptance limits should be changed. In this way method development and validation is an iterative process. For example, in liquid chromatography selectivity is achieved through selection of mobile-phase composition. For quantitative measurements the resolution factor between two peaks should be 2.5 or higher. If this value is not achieved, the mobile phase composition needs further optimization. 

Our preliminary results suggest that the described concept of the simulation of micelles and membranes as layered COSMO-RS liquids is a promising new approach to an efficient simulation of such systems, but more development and validation work is... 

Improvement schemes can be defined as a succession of individual interlaboratory studies in which several laboratories analyse the same test samples for the same characteristics (usually the content of an analyte), following a similar protocol to validate each individual step of their own analytical method (Quevauviller, 1999a). They enable laboratories to develop and validate all steps of new or existing analytical procedure(s) in adequately organised successive exercises which may be considered as preliminary studies for laboratory or method performance studies or certification of RMs (Griepink and Stoeppler, 1992 Quevauviller, 1998b). Such programmes are particularly valuable in the case of speciation studies since the analytical procedures include several complex and critical steps. 

Fyhr et al. [201] reviewed several commercially available oxygen analyzers intended for the analysis of oxygen in the headspace of vials. However, preliminary validation revealed insufficient reproducibility and linearity. The authors developed headspace analysis systems. Sample volumes down to about 2.5 ml could be used without significant errors. Sample recovery was in the range 100-102%. It was necessary to measure the head-space pressure and volume in order to be able to present the assay in partial oxygen pressure or in millimoles of oxygen. Up to 40 vials per hour could be analyzed using this technique. 

X-ray structural analysis or, more generally, structure determination based on the analysis of diffraction pictures, is very a reliable method delivering us enormous amount of chemical information. These techniques are commonly considered objective, that is, independent of preliminary assumptions. In this chapter, some criticism of this common belief is given, though it is not the intention of the authors to question the importance and validity of the diffraction techniques. On the contrary, our aim is to stress the importance and value of structural data derived from diffraction, but we would also emphasize the important role of creating and developing structural models by other approaches and subsequent use of the models in structure analysis. Molecular modeling is one, if not the most important, possibility to do this. 

In summary, and at the risk of repetition, it must be stressed that the development of analytical methodology for the assessment of human exposure to pesticides is a complex process. Careful attention to planning of the research is of utmost importance. As much information as possible about transformation, storage and excretion of the pesticides of interest should be gathered. Preliminary work should focus on the analytical behavior of parent compounds and metabolites. The combination of these aspects with reliable analytical standards and a sound quality assurance program should yield valid analytical methodology. 

Figure 13.10 Depiction of the recursive process used by NCTR to develop QSAR models for predicting ER binding. The process starts with an initial set of chemicals from the literature for QSAR modeling. Next, the preliminary QSAR models are used prospectively to define a set of chemicals that will further improve the model s robustness and predictive capability. The new chemicals are assayed, and these data are then used to challenge and refine the QSAR models. Validation of the model is critical. The process emphasizes the living model concept.

---